Difference between revisions of "Samarium-153 (Quadramet)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http://www.lantheus.com/assets/quadramet-us-outsert-513145-0114-format-2-3-4-2014.pdf Samarium-153 (Quadramet) package insert]</ref><ref>[[ | + | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http://www.lantheus.com/assets/quadramet-us-outsert-513145-0114-format-2-3-4-2014.pdf Samarium-153 (Quadramet) package insert]</ref><ref>[[:File:Samarium153a.pdf|Samarium-153 (Quadramet) package insert (locally hosted backup)]]</ref><ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000150/WC500041751.pdf Samarium-153 (Quadramet) alternative package insert]</ref><ref>[[:File:Samarium153b.pdf|Samarium-153 (Quadramet) alternative package insert (locally hosted backup)]]</ref><ref>[http://www.lantheus.com/products/overview/quadramet/ Quadramet manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1997-03-28: Initial approval for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. |
| − | + | ==History of changes in EMA indication== | |
| + | *1998-02-04: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' 153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), lexidronam pentasodium, samarium [153 SM], samarium Sm 153 lexidronam injection | *'''Generic names:''' 153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), lexidronam pentasodium, samarium [153 SM], samarium Sm 153 lexidronam injection | ||
| Line 31: | Line 32: | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
| + | [[Category:EMA approved in 1998]] | ||
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 1997-03-28: Initial approval for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
History of changes in EMA indication
- 1998-02-04: Initial authorization
Also known as
- Generic names: 153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), lexidronam pentasodium, samarium [153 SM], samarium Sm 153 lexidronam injection
- Brand name: Quadramet
References
- ↑ 1.0 1.1 Samarium-153 (Quadramet) package insert
- ↑ Samarium-153 (Quadramet) package insert (locally hosted backup)
- ↑ Samarium-153 (Quadramet) alternative package insert
- ↑ Samarium-153 (Quadramet) alternative package insert (locally hosted backup)
- ↑ Quadramet manufacturer's website
- ↑ Samarium-153 (Quadramet) patient drug information (UpToDate)